Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK2 | Q9HBH9 | 20/20 | 0.84 |
| ▸ | MKNK1 | Q9BUB5 | 7/20 | 0.84 |
| ▸ | EIF4E | P06730 | 4/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20576704 | 1.00 | MKNK2 (0.84) | MKNK2MKNK1EIF4E | |
| SCHEMBL23049882 | 1.00 | MKNK2 (0.84) | MKNK2MKNK1EIF4E | |
| SCHEMBL20575706 | 0.93 | MKNK2 (0.96) | MKNK2MKNK1EIF4E | |
| SCHEMBL20575252 | 0.91 | MKNK2 (1.00) | MKNK2MKNK1EIF4E | |
| SCHEMBL23049793 | 0.91 | MKNK2 (0.98) | MKNK2MKNK1EIF4E | |
| SCHEMBL20576066 | 0.89 | MKNK2 (0.92) | MKNK2MKNK1EIF4E | |
| SCHEMBL20576758 | 0.86 | MKNK2 (0.79) | MKNK2MKNK1EIF4E | |
| SCHEMBL20575389 | 0.86 | MKNK2 (0.79) | MKNK2MKNK1EIF4E | |
| SCHEMBL23049810 | 0.85 | MKNK2 (1.00) | MKNK2MKNK1EIF4E | |
| SCHEMBL20576687 | 0.85 | MKNK2 (1.00) | MKNK2MKNK1EIF4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3792264-B1 | PYRROPYRIMIDINE COMPOUNDS AS MNKS INHIBITORS | LIFEARC (GB) | 2024-01-03 | — | — | EP | disclosed |
| EP-3792264-A1 | PYRROPYRIMIDINE COMPOUNDS AS MNKS INHIBITORS | LifeArc (GB) | 2021-03-17 | — | — | EP | disclosed |
| EP-3377494-B1 | PYRROPYRIMIDINE COMPOUNDS AS MNKS INHIBITORS | LIFEARC (GB) | 2021-03-03 | — | — | EP | disclosed |
| EP-3377494-B1 | PYRROPYRIMIDINE COMPOUNDS AS MNKS INHIBITORS | LIFEARC (GB) | 2021-03-03 | — | — | EP | disclosed |
| US-10604524-B2 | Pyrropyrimidine compounds as MNKs inhibitors | LIFE ARC (GB) | 2020-03-31 | — | — | US | disclosed |
| US-20180346469-A1 | Pyrropyrimidine Compounds As MNKS Inhibitors | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2018-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180346469-A1 | Pyrropyrimidine Compounds As MNKS Inhibitors | NR0B1, NR4A1, NR2E1 | MKNK2 752/4885MKNK1 573/4885EIF4E 2826/4885 |
| US-10604524-B2 | Pyrropyrimidine compounds as MNKs inhibitors | NR0B1, NR2E1, HRH4 | MKNK2 676/4885MKNK1 507/4885EIF4E 2686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.